We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology
News

Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology

Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology
News

Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lumera Extends Collaborative Research Agreement with the Institute for Systems Biology "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lumera Corporation has announced that it has extended its collaboration agreement with the Institute for Systems Biology (ISB).

The goal of the collaboration is to use Lumera’s ProteomicProcessor™ to identify biomarkers associated with drug toxicity and cancer.

As previously announced, ISB researchers have demonstrated a label-free assay to determine protein expression patterns using a panel of specific antibodies printed on Lumera’s NanoCapture-Gold™ microarray and analyzed on the company’s ProteomicProcessor ™ instrument system.

“We are quite pleased with the progress of the past year,” said Dr. Leroy Hood, President of the Institute for Systems Biology. “Lumera’s platform provides unique advantages in biomarker discovery and we are committed to moving the science forward.”

“Early results from ISB have been proof positive that our technology adds significant value to the biomarker discovery market. We feel that with a continued emphasis on this project, we will arrive at a very important publication and will establish methods by which others will be able to develop their own assays,” said Dr. Timothy Londergan, Lumera’s Bioscience Business Unit.

As previously discussed by the company, biomarkers are important indicators of disease and their identification can lead to the development of targeted drug solutions to prevent or arrest the disease.

Advertisement